Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy

Deal Prices Target Company At Big Premium

 
• By Mandy Jackson

Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.

Merger and Acquisitions, partnership or work together
Sobi will merge CTI's Vonjo into its growing hematology franchise • Source: Shutterstock

More from Deals

More from Business